相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma
Rolando Pérez-Lorenzo et al.
Oncotarget (2021)
Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model
Shuyang S. Qin et al.
CANCERS (2021)
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Elena Shklovskaya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Enhanced Antitumor Response to Immune Checkpoint Blockade Exerted by Cisplatin-Induced Mutagenesis in a Murine Melanoma Model
Falih M. Gorgun et al.
FRONTIERS IN ONCOLOGY (2021)
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma
Benjamin P. Fairfax et al.
NATURE MEDICINE (2020)
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Jenny H. Lee et al.
NATURE COMMUNICATIONS (2020)
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso et al.
CANCER CELL (2020)
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Elena Shklovskaya et al.
CANCERS (2020)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Alexander C. Huang et al.
NATURE MEDICINE (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2019)
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Yochai Wolf et al.
CELL (2019)
Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression
Anders Etzerodt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells
Evelyn Menares et al.
NATURE COMMUNICATIONS (2019)
Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin
Simone L. Park et al.
NATURE (2019)
The YUMMER.G mouse melanoma model recapitulates the heterogeneous response to immune checkpoint blockade based on patient sex
Julie Y. Ramseier et al.
CANCER RESEARCH (2019)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade
Natalie J. Neubert et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
IFN gamma-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
Ryan S. Lane et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model
Jake Wang et al.
PIGMENT CELL & MELANOMA RESEARCH (2017)
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
Blanca Homet Moreno et al.
ONCOIMMUNOLOGY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen
Elena Shklovskaya et al.
IMMUNOLOGY AND CELL BIOLOGY (2016)
What does PD-L1 positive or negative mean?
Antoni Ribas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Katrina Meeth et al.
PIGMENT CELL & MELANOMA RESEARCH (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Blanca Homet Moreno et al.
CANCER IMMUNOLOGY RESEARCH (2016)
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
Marzia Scortegagna et al.
CANCER RESEARCH (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c+MHCII+ Macrophages and Dendritic Cells
Julie Helft et al.
IMMUNITY (2015)
Monocyte-Derived Dendritic cells are essential for cD8+ T cell activation and antitumor responses after local immunotherapy
Sabine Kuhn et al.
FRONTIERS IN IMMUNOLOGY (2015)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)